Pages that link to "Item:Q70258"
From MaRDI portal
The following pages link to Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer (Q70258):
Displaying 50 items.
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261) (← links)
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach (Q93669) (← links)
- escalation (Q133814) (← links)
- A conversation with Nancy Flournoy (Q254418) (← links)
- A note on continual reassessment method (Q274178) (← links)
- Efficiency of bridging between related dose finding studies (Q357429) (← links)
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates (Q419309) (← links)
- A note on the robustness of the continual reassessment method (Q433569) (← links)
- Adaptive Bayesian compound designs for dose finding studies (Q434557) (← links)
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
- On the consistency of the continual reassessment method with multiple toxicity constraints (Q499432) (← links)
- The treatment versus experimentation dilemma in dose finding studies (Q538132) (← links)
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach (Q725696) (← links)
- Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Approximate dynamic programming and its applications to the design of Phase I cancer trials (Q903295) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- Convergence properties of sequential Bayesian \(D\)-optimal designs (Q958799) (← links)
- Unifying CRM and EWOC designs for phase I cancer clinical trials (Q1007501) (← links)
- Optimal Bayesian-feasible dose escalation for cancer phase I trials (Q1265963) (← links)
- Operating characteristics of the standard phase I clinical trial design. (Q1285808) (← links)
- trialr (Q1350867) (← links)
- Using a one-parameter model to sequentially estimate the root of a regression function. (Q1583204) (← links)
- Optimal sequential designs in phase I studies (Q1621308) (← links)
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
- Methodology and application of adaptive and sequential approaches in contemporary clinical trials (Q1929694) (← links)
- Number of patients per cohort and sample size considerations using dose escalation with overdose control (Q1929695) (← links)
- Analysis of ``learn-as-you-go'' (LAGO) studies (Q2039787) (← links)
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
- Optimal designs for dose-escalation trials and individual allocations in cohorts (Q2084331) (← links)
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
- Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors (Q2233150) (← links)
- On optimal designs for clinical trials: an updated review (Q2301225) (← links)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
- Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data (Q2359487) (← links)
- An application of reinforced urn processes to determining maximum tolerated dose (Q2373664) (← links)
- A new look at evaluating MTD designs in cancer research (Q2431683) (← links)
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Cumulative cohort design for dose-finding (Q2455719) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Optimal adaptive generalized Pólya urn design for multi-arm clinical trials (Q2482603) (← links)
- Theoretical study of the continual reassessment method (Q2492919) (← links)
- Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
- Multivariate Markov models for the conditional probability of toxicity in phase II trials (Q2792772) (← links)
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803) (← links)
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
